Françoise Besançon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Françoise Besançon has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Julie Mathieu
INSERM Unité 685, IFR 105, Hopital St-Louis, 1 avenue Claude Vellefaux, Paris cedex, France
2 shared publicationsJ Mathieu
INSERM Unité 685, Institut Universitaire d'Hématologie, Paris Cedex 10, France
1 shared publicationM Flexor
AP-HP, Hôpital St Louis, Paris Cedex 10, France
1 shared publicationM Lanotte
INSERM Unité 685, Institut Universitaire d'Hématologie, Paris Cedex 10, France
1 shared publicationMichel Lanotte
INSERM U685, Centre Hayem, Hôpital St Louis, 1 avenue Claude Vellefaux, 75475 Paris, France
1 shared publicationStéphane Giraudier
INSERM U362, Institut Gustave Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France
1 shared publication
Latest Publications
- 17 December 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (24) , 3361-3370
A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNFα and all-trans retinoic acid in APL cells
When administrated by isolated limb perfusion, tumor necrosis factor α (TNFα) is an efficient antitumor agent that improves drug penetration and destroys angiogenic vessels. Moreover, the pronounced potentiation of TNFα-induced apoptosis by NF-κB inhibitors suggest that these compounds could enhance TNFα antitumor efficacy through direct induction of tumor cell apoptosis. Therefore, attempts at amplifying signaling pathways that mediate TNFα antitumor effects could help to design combination therapies improving its efficiency. We report that nanomolar concentrations of all-trans retinoic acid (ATRA) amplify TNFα-induced apoptosis in APL cells expressing a specific repressor of NF-κB activation. This effect is abolished by the pan-caspase inhibitor, Z-VAD-fmk and by caspase-8 and -9 inhibitors. Cell death is accompanied by a drop of mitochondrial potential and by poly (ADP-ribose) polymerase (PARP) activation. Using specific PARP-1 inhibitors and siRNAs, we show that PARP-1 is essential for the synergistic apoptotic effect and c-Jun N-terminal kinase 1 (JNK1) activation triggered by the ATRA/TNFα combination. JNK1 siRNAs reduce ATRA/TNFα-induced apoptosis, mitochondrial release of cytochrome c and caspase-9 activation. Altogether, these results identify a novel mechanism of PARP-1-induced apoptosis, in which JNK1 provides a link between PARP-1 activation and mitochondrial pathway of caspase-9 activation. This study also suggests that inclusion of nanomolar doses of ATRA could be clinically beneficial in amplifying TNFα-induced antitumor signals.
- 17 December 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (24) , 3361-3370
A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNFα and all-trans retinoic acid in APL cells
When administrated by isolated limb perfusion, tumor necrosis factor α (TNFα) is an efficient antitumor agent that improves drug penetration and destroys angiogenic vessels. Moreover, the pronounced potentiation of TNFα-induced apoptosis by NF-κB inhibitors suggest that these compounds could enhance TNFα antitumor efficacy through direct induction of tumor cell apoptosis. Therefore, attempts at amplifying signaling pathways that mediate TNFα antitumor effects could help to design combination therapies improving its efficiency. We report that nanomolar concentrations of all-trans retinoic acid (ATRA) amplify TNFα-induced apoptosis in APL cells expressing a specific repressor of NF-κB activation. This effect is abolished by the pan-caspase inhibitor, Z-VAD-fmk and by caspase-8 and -9 inhibitors. Cell death is accompanied by a drop of mitochondrial potential and by poly (ADP-ribose) polymerase (PARP) activation. Using specific PARP-1 inhibitors and siRNAs, we show that PARP-1 is essential for the synergistic apoptotic effect and c-Jun N-terminal kinase 1 (JNK1) activation triggered by the ATRA/TNFα combination. JNK1 siRNAs reduce ATRA/TNFα-induced apoptosis, mitochondrial release of cytochrome c and caspase-9 activation. Altogether, these results identify a novel mechanism of PARP-1-induced apoptosis, in which JNK1 provides a link between PARP-1 activation and mitochondrial pathway of caspase-9 activation. This study also suggests that inclusion of nanomolar doses of ATRA could be clinically beneficial in amplifying TNFα-induced antitumor signals.
- Open Access
- 18 July 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (7) , 1723-1727
Clinically tolerable concentrations of arsenic trioxide induce p53‐independent cell death and repress NF‐κB activation in Ewing sarcoma cells
Ewing sarcoma (ES), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly FLI‐1. Despite significant advances with multiagent chemotherapy, surgery and radiotherapy, about 40% of ES patients still die from the disease. It is therefore necessary to explore novel agents for possible treatment of this tumor. Here the authors investigated the sensitivity of ES cells to clinically tolerable concentrations of arsenic trioxide (As2O3), a compound known to induce differentiation and apoptosis of other types of malignant cells. The authors report that As2O3 uniformly induced death of 6 ES‐derived cell lines irrespective of their p53 status. As2O3 resulted in an apoptotic phenotype which was inhibited by the broad‐spectrum caspase inhibitor ZVAD‐fmk. These effects correlated with prolonged c‐jun N‐terminal kinase activation, which is a signal for apoptosis in ES cells. As2O3 also decreased basal and cytokine‐induced NF‐κB activity. Since the authors previously demonstrated that NF‐κB exerts an antiapoptotic action in ES cells, As2O3 treatment may also result in a sensitization of these cells to other drugs used in combination therapy. These effects, combined with its antiangiogenic action, define As2O3 as a good candidate for future protocols to improve treatments of Ewing sarcomas, irrespective of the p53 status of the tumor.
- 18 July 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (7) , 1723-1727
Open AccessClinically tolerable concentrations of arsenic trioxide induce p53‐independent cell death and repress NF‐κB activation in Ewing sarcoma cells
Ewing sarcoma (ES), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly FLI‐1. Despite significant advances with multiagent chemotherapy, surgery and radiotherapy, about 40% of ES patients still die from the disease. It is therefore necessary to explore novel agents for possible treatment of this tumor. Here the authors investigated the sensitivity of ES cells to clinically tolerable concentrations of arsenic trioxide (As2O3), a compound known to induce differentiation and apoptosis of other types of malignant cells. The authors report that As2O3 uniformly induced death of 6 ES‐derived cell lines irrespective of their p53 status. As2O3 resulted in an apoptotic phenotype which was inhibited by the broad‐spectrum caspase inhibitor ZVAD‐fmk. These effects correlated with prolonged c‐jun N‐terminal kinase activation, which is a signal for apoptosis in ES cells. As2O3 also decreased basal and cytokine‐induced NF‐κB activity. Since the authors previously demonstrated that NF‐κB exerts an antiapoptotic action in ES cells, As2O3 treatment may also result in a sensitization of these cells to other drugs used in combination therapy. These effects, combined with its antiangiogenic action, define As2O3 as a good candidate for future protocols to improve treatments of Ewing sarcomas, irrespective of the p53 status of the tumor.
- 25 July 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (48) , 7145-7155
Retinoid-induced activation of NF-κB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells
All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-B occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-B activation did not affect granulocytic differentiation. Importantly, NF-B inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-B activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-B activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-B signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome.
- 25 July 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (48) , 7145-7155
Retinoid-induced activation of NF-κB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells
All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-B occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-B activation did not affect granulocytic differentiation. Importantly, NF-B inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-B activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-B activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-B signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome.